Geron earnings date
Geron (GON) Q3 2026 Earnings Report
DE:GON Q3 2026 EPS Results
- Actual EPS
- EUR 0.00
- Consensus EPS
- -EUR 0.01
- Beat/Miss
- Beat by +EUR 0.01
- One Year Ago EPS
- -EUR 0.03
DE:GON Q3 2026 Revenue Results
- Actual Revenue
- EUR 53.89M
- Expected Revenue
- EUR 54.04M
- Beat/Miss
- Missed by -EUR 151.31K
- YoY Revenue Growth
- +27.45%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- Before Open
- Conference Call
- Wednesday, November 4, 2026
Geron's next earnings date is estimated for March 3, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was predominantly positive, with four consecutive quarters of RYTELO demand growth, 27% year-over-year revenue growth, reaffirmed revenue guidance, lower operating expenses, a strong cash position, and the start of a European commercial launch. The principal negative was the discontinuation of the IMpactMF trial after it was deemed unlikely to meet its overall survival endpoint, although management stated that no new safety signals changed imetelstat's known safety profile.
Geron reiterated 2026 RYTELO net revenue guidance at $220 million to $240 million, expecting to come in at the mid- to high end of the $220 million to $240 million range, and lowered total operating expense guidance from $230 million to $240 million to the range of $220 million to $230 million; for the remainder of 2026, gross to net is expected to be in the low to mid-20s, inventory is expected to remain within the 2% to 4% guidance, and RYTELO is expected to be commercially available in Germany by the end of this year, with plans to follow in 2027. Management said there will be some increases next year as the Europe strategy matures and for the post-marketing commitment in clinical trials, while the remainder of OpEx will be steady.
- RYTELO Demand and Revenue GrowthRYTELO demand increased 10% quarter-over-quarter in the third quarter, while net product revenue grew 5% sequentially to $60.1 million and increased 27% year-over-year from $47.2 million in Q3 2025.
- 2026 Revenue Guidance ReiteratedGeron reiterated its 2026 RYTELO net revenue guidance of $220 million to $240 million and expects to achieve the mid- to high end of that range, supported by consistent quarter-over-quarter net revenue growth.
- Continued Expansion in Prescribing AccountsRYTELO prescribing accounts increased 8% in the third quarter, with the account base expanding to more than 1,700 since launch, predominantly through community practices.
- Growing First- and Second-Line Patient AdoptionFirst- and second-line patient starts represented 36% on a rolling 12-month basis. Management said adoption in the community setting remains a key driver and that thousands of patients could benefit from RYTELO.
- European Commercial Launch UnderwayGeron initiated a gated commercial launch in targeted European markets, with RYTELO expected to be commercially available in Germany by the end of 2026 and additional countries, including France, planned to follow in 2027.
- Flexible European Commercialization ModelThe European strategy is designed to broaden access while retaining strategic control of pricing, avoiding the need to establish full infrastructure in each market or make a large upfront investment, and preserving partnership flexibility.
- Improved Gross-to-Net PerformanceGross-to-net deductions decreased to 19.3% for the three months ended September 30, 2026, compared with 21.6% in the same period of 2025. Geron continues to expect gross-to-net deductions in the low to mid-20s for the remainder of 2026.
- Lower Operating Expenses and Updated GuidanceYear-to-date operating expenses were down 9% versus the prior year. Total operating expenses excluding cost of goods sold were $48.3 million in Q3 2026, compared with $60.1 million in Q3 2025, and full-year operating expense guidance was reduced from $230 million to $240 million to $220 million to $230 million.
- Reduced Research and Development ExpensesThird-quarter research and development expenses decreased to $12.7 million from $21.1 million in Q3 2025, primarily due to lower headcount costs following the December 2025 workforce reduction and lower clinical chemistry, manufacturing and control costs.
- Reduced Selling, General and Administrative ExpensesThird-quarter selling, general and administrative expenses declined to $35.7 million from $39.0 million in Q3 2025, primarily due to lower general and administrative personnel-related expenses following the December 2025 workforce reduction.
- Strong Cash Position and Business Development FlexibilityCash, cash equivalents, restricted cash and marketable securities totaled approximately $339 million as of September 30, 2026, compared with $327 million as of June 30, 2026. Management said this balance supports current operations and provides flexibility to pursue business development opportunities.
- Positive Clinical and Real-World Evidence for RYTELOPresentations at global and regional hematology meetings continued to support RYTELO's differentiated profile, including disease-modifying activity, durable clinical outcomes, hemoglobin improvement and transfusion independence in low-risk MDS. A real-world evidence poster showed meaningful hemoglobin improvement despite short treatment duration in U.S. community oncology practice.
- Expanded Scientific and Medical EngagementGeron presented additional data at the Japanese Society of Hematology and German, Austrian and Swiss hematology meetings, published two manuscripts in peer-reviewed journals, and had six abstracts accepted for the 68th ASH Annual Meeting.
- Recognition for RYTELO and Telomerase ResearchGeron was nominated for the Prix Galien USA Award for Best Product for Orphan or Rare Diseases, recognizing its work in telomerase inhibition and its focus on addressing unmet needs in low-risk MDS.
- Targeted Future Investment and Business Development StrategyManagement said it will continue disciplined capital allocation, with planned increases in 2027 as the European strategy matures and post-marketing commitment clinical trials progress. Geron is evaluating selective hematology or oncology business development opportunities, particularly community-based diseases, and described a potential 'string of pearls' approach involving assets with a few hundred million dollars of potential peak sales.
- Inventory Remained Within Prior GuidanceManagement said inventory remained within the previously communicated 2% to 4% guidance range.
DE:GON Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 03, 2027 | 2026 (Q4) | 0.00- | -0.04 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | -0.010.00 | -0.03 | 100.00% (+0.03) | |
| Aug 05, 2026 | 2026 (Q2) | -0.01-0.02 | -0.02 | 0.00% (+0.00) | |
| May 06, 2026 | 2026 (Q1) | -0.02-0.01 | -0.03 | 66.67% (+0.02) | |
| Feb 25, 2026 | 2025 (Q4) | -0.03-0.04 | -0.04 | -25.00% (-0.01) | |
| Nov 05, 2025 | 2025 (Q3) | -0.03-0.03 | -0.04 | 25.00% (+0.01) | |
| Aug 06, 2025 | 2025 (Q2) | -0.03-0.02 | -0.09 | 80.00% (+0.07) | |
| May 07, 2025 | 2025 (Q1) | -0.03-0.03 | -0.08 | 66.67% (+0.05) | |
| Feb 26, 2025 | 2024 (Q4) | -0.02-0.04 | -0.08 | 55.56% (+0.04) | |
| Nov 07, 2024 | 2024 (Q3) | -0.08-0.04 | -0.07 | 50.00% (+0.04) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
